دورية أكاديمية
Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?
| العنوان: | Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs? |
|---|---|
| المؤلفون: | Jongbloed,Elisabeth M, Blommestein,Hedwig M, van Schoubroeck,Hannah M, Martens,John WM, Wilting,Saskia M, Uyl-de Groot,Carin A, Jager,Agnes |
| بيانات النشر: | Dove Press |
| سنة النشر: | 2023 |
| المجموعة: | Dove Medical Press |
| مصطلحات موضوعية: | Breast Cancer: Targets and Therapy |
| الوصف: | Elisabeth M Jongbloed,1 Hedwig M Blommestein,2 Hannah M van Schoubroeck,2 John WM Martens,1 Saskia M Wilting,1 Carin A Uyl-de Groot,2 Agnes Jager1 1Department of Medical Oncology; Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 2Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, the NetherlandsCorrespondence: Elisabeth M Jongbloed, Department of Medical Oncology; Erasmus MC Cancer Institute, Dr. Molenwaterplein 40, Rotterdam, 3014 GD, the Netherlands, Tel +31 107044375, Email e.jongbloed@erasmusmc.nlPurpose: The addition of two years of abemaciclib treatment to standard adjuvant endocrine therapy in all patients with high risk ER+, HER2- early breast cancer (EBC) has been approved by the US Food and Drug Administration (FDA). Pre-selection of patients with an immediate risk of recurrence within the group of clinically high risk patients using detection of minimal residual disease (MRD) using patient-informed circulating tumor DNA assays during follow-up could enhance efficacy. Here, we investigate the cost-effectiveness of the addition of two years abemaciclib in all high risk HR+, HER2- patients and in MRD-guided high risk patients only.Methods: Two semi-Markov models were developed to evaluate the cost-effectiveness of adding two years of abemaciclib compared to “standard treatmentâ€: 1) “abemaciclib all†and 2) “MRD-guided abemaciclib†using MRD-guidance. Data of the MonarchE trial were used to model the invasive disease-free survival (iDFS). Since iDFS and overall survival (OS) data of abemaciclib were currently limited, abemaciclib effects were extrapolated using a favorable, intermediate and unfavorable effect scenario.Results: The addition of abemaciclib in all high-risk EBC patients prolonged iDFS slightly (0.04 additional quality adjusted life years (QALYs)) and led to higher costs compared to standard ET, leading to a high incremental cost effectiveness ratio (ICER) of € 1,551,876/QALY. Neither the favorable effect scenario (additional 1.09 QALYs) was ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | https://www.dovepress.com/cost-effectiveness-of-abemaciclib-in-early-breast-cancer-patients-one--peer-reviewed-fulltext-article-BCTTTest |
| الإتاحة: | https://doi.org/10.2147/BCTT.S387375Test https://www.dovepress.com/cost-effectiveness-of-abemaciclib-in-early-breast-cancer-patients-one--peer-reviewed-fulltext-article-BCTTTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.4A068C6E |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |